Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TGR-1202 Clear all
Terminated Phase 2 Interventional Results available

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

NCT03828448
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 2, 2026, 10:54 AM EDT
Active, not recruiting Phase 1 Interventional

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

NCT03283137
View directory record Official record
Conditions
CLL, B-cell Non Hodgkin Lymphoma
Interventions
TGR-1202, Pembrolizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

NCT02006485
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
Interventions
Ublituximab + TGR-1202, Ublituximab + TGR-1202 + ibrutinib, Ublituximab + TGR-1202 + bendamustine
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
6
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Duarte, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

NCT03379051
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions
Venetoclax, Umbralisib, Ublituximab, Lenalidomide
Drug · Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 3 Interventional Results available

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

NCT02612311
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Ublituximab, TGR-1202, Chlorambucil
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

NCT03364231
View directory record Official record
Conditions
Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma
Interventions
Umbralisib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT01767766
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Hodgkin's Lymphoma
Interventions
TGR-1202
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Sarasota, Florida • Hackensack, New Jersey • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Results available

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

NCT02268851
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Interventions
TGR-1202, Ibrutinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
5
States / cities
Monterey, California • Hartford, Connecticut • Brewer, Maine + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

NCT04016805
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ublituximab, Umbralisib, Ibrutinib, Venetoclax, Acalabrutinib Oral Capsule
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

TGR1202 in Relapsed and Refractory Follicular Lymphoma

NCT03178201
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
TGR-1202
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2Phase 3 Interventional

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

NCT02793583
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib, Bendamustine
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
111
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

NCT03801525
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ublituximab, Umbralisib, Venetoclax
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

NCT02656303
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ublituximab, Umbralisib
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
69
States / cities
Huntsville, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

NCT04692155
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Ublituximab, Umbralisib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

NCT04163718
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Umbralisib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

NCT03207256
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
TGR-1202, TGR-1202 + Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
17
States / cities
Huntsville, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

NCT02493530
View directory record Official record
Conditions
Myelofibrosis, Polycythemia Vera
Interventions
TGR-1202, ruxolitinib
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Aurora, Colorado • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

NCT02867618
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Non-hodgkin
Interventions
Carfilzomib, TGR-1202
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

NCT02742090
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Umbralisib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Huntsville, Alabama • Washington D.C., District of Columbia • Fort Myers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

NCT02574663
View directory record Official record
Conditions
Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST)
Interventions
TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin + Folinic acid + Fluorouracil, Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

NCT03919175
View directory record Official record
Conditions
Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1, Follicular Lymphoma Grade 2, Follicular Lymphoma Grade IIIa, Marginal Zone Lymphoma, Marginal Zone B Cell Lymphoma
Interventions
Umbralisib, Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 2, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional Results available

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03776864
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
Pembrolizumab, Umbralisib
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 2, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02874404
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, PI3K-delta Inhibitor TGR-1202
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 2, 2026, 10:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

NCT04783415
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib, Ublituximab, Umbralisib
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 2, 2026, 10:54 AM EDT